UK markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.7501-0.0551 (-6.84%)
At close: 04:00PM EDT
0.8000 +0.05 (+6.65%)
After hours: 07:42PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.8052
Open0.8000
Bid0.7247 x 100
Ask0.7707 x 200
Day's range0.7500 - 0.8000
52-week range0.5000 - 4.4500
Volume250,237
Avg. volume576,831
Market cap41.012M
Beta (5Y monthly)0.73
PE ratio (TTM)N/A
EPS (TTM)-2.2600
Earnings date05 Aug 2024 - 09 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.23
  • Zacks

    Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates

    Cara (CARA) delivered earnings and revenue surprises of -47.37% and 5.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Cara Therapeutics Reports First Quarter 2024 Financial Results

    Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2024. “Our notalgia paresthetic

  • GlobeNewswire

    Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024

    STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close. The press release will be available under “Press Releases” in the Investors section of the Company’s website at www.CaraTherapeutics.com. Abo